nodes	percent_of_prediction	percent_of_DWPC	metapath
Dasatinib—EPHB4—breast cancer	0.115	0.291	CbGaD
Dasatinib—BTK—Mitoxantrone—breast cancer	0.0666	0.245	CbGbCtD
Dasatinib—ERBB3—breast cancer	0.0526	0.134	CbGaD
Dasatinib—CSF1R—breast cancer	0.0499	0.127	CbGaD
Dasatinib—ABL1—breast cancer	0.0388	0.0985	CbGaD
Dasatinib—SRC—breast cancer	0.0351	0.0892	CbGaD
Dasatinib—KIT—breast cancer	0.0311	0.0791	CbGaD
Dasatinib—FMO3—Tamoxifen—breast cancer	0.0283	0.104	CbGbCtD
Dasatinib—CYP1B1—breast cancer	0.025	0.0635	CbGaD
Dasatinib—ABCG2—breast cancer	0.0172	0.0438	CbGaD
Dasatinib—CYP1A1—breast cancer	0.0135	0.0343	CbGaD
Dasatinib—CYP1A1—Toremifene—breast cancer	0.013	0.0478	CbGbCtD
Dasatinib—CYP1B1—Tamoxifen—breast cancer	0.0108	0.0398	CbGbCtD
Dasatinib—CYP1B1—Mitoxantrone—breast cancer	0.0106	0.0388	CbGbCtD
Dasatinib—CYP3A4—breast cancer	0.00862	0.0219	CbGaD
Dasatinib—CYP1B1—Paclitaxel—breast cancer	0.00842	0.0309	CbGbCtD
Dasatinib—ABCB1—breast cancer	0.00717	0.0182	CbGaD
Dasatinib—CYP1A2—Anastrozole—breast cancer	0.00635	0.0233	CbGbCtD
Dasatinib—CYP1B1—Docetaxel—breast cancer	0.00609	0.0224	CbGbCtD
Dasatinib—CYP1A2—Toremifene—breast cancer	0.00581	0.0213	CbGbCtD
Dasatinib—CYP3A5—Lapatinib—breast cancer	0.00569	0.0209	CbGbCtD
Dasatinib—ABCG2—Tamoxifen—breast cancer	0.00514	0.0189	CbGbCtD
Dasatinib—ABCB1—Toremifene—breast cancer	0.00508	0.0187	CbGbCtD
Dasatinib—ABCG2—Mitoxantrone—breast cancer	0.00502	0.0184	CbGbCtD
Dasatinib—CYP1A1—Tamoxifen—breast cancer	0.00475	0.0174	CbGbCtD
Dasatinib—CYP1B1—Doxorubicin—breast cancer	0.00454	0.0167	CbGbCtD
Dasatinib—CYP3A4—Exemestane—breast cancer	0.00439	0.0161	CbGbCtD
Dasatinib—ABCG2—Paclitaxel—breast cancer	0.004	0.0147	CbGbCtD
Dasatinib—ABCG2—Irinotecan—breast cancer	0.00395	0.0145	CbGbCtD
Dasatinib—ABCG2—Fluorouracil—breast cancer	0.00379	0.0139	CbGbCtD
Dasatinib—ABCG2—Carboplatin—breast cancer	0.00377	0.0138	CbGbCtD
Dasatinib—CYP3A4—Letrozole—breast cancer	0.00373	0.0137	CbGbCtD
Dasatinib—ABCB1—Lapatinib—breast cancer	0.0037	0.0136	CbGbCtD
Dasatinib—CYP3A4—Anastrozole—breast cancer	0.00333	0.0122	CbGbCtD
Dasatinib—CYP3A4—Toremifene—breast cancer	0.00304	0.0112	CbGbCtD
Dasatinib—ABCG2—Docetaxel—breast cancer	0.00289	0.0106	CbGbCtD
Dasatinib—CYP3A5—Tamoxifen—breast cancer	0.00285	0.0105	CbGbCtD
Dasatinib—CYP3A4—Fulvestrant—breast cancer	0.00283	0.0104	CbGbCtD
Dasatinib—CYP3A4—Thiotepa—breast cancer	0.00252	0.00926	CbGbCtD
Dasatinib—CYP3A4—Ixabepilone—breast cancer	0.00231	0.00847	CbGbCtD
Dasatinib—CYP3A4—Lapatinib—breast cancer	0.00222	0.00815	CbGbCtD
Dasatinib—CYP3A5—Paclitaxel—breast cancer	0.00222	0.00815	CbGbCtD
Dasatinib—CYP3A5—Irinotecan—breast cancer	0.00219	0.00804	CbGbCtD
Dasatinib—ABCG2—Doxorubicin—breast cancer	0.00216	0.00793	CbGbCtD
Dasatinib—CYP1A2—Tamoxifen—breast cancer	0.00212	0.00779	CbGbCtD
Dasatinib—ABCG2—Methotrexate—breast cancer	0.00209	0.00768	CbGbCtD
Dasatinib—ABCB1—Vinorelbine—breast cancer	0.00205	0.00755	CbGbCtD
Dasatinib—ABCB1—Tamoxifen—breast cancer	0.00185	0.00681	CbGbCtD
Dasatinib—ABCB1—Mitoxantrone—breast cancer	0.00181	0.00665	CbGbCtD
Dasatinib—CYP3A4—Raloxifene—breast cancer	0.00168	0.00618	CbGbCtD
Dasatinib—CYP3A5—Docetaxel—breast cancer	0.0016	0.00589	CbGbCtD
Dasatinib—ABCB1—Gemcitabine—breast cancer	0.0016	0.00587	CbGbCtD
Dasatinib—CYP1A2—Fluorouracil—breast cancer	0.00156	0.00574	CbGbCtD
Dasatinib—ABCB1—Paclitaxel—breast cancer	0.00144	0.0053	CbGbCtD
Dasatinib—ABCB1—Irinotecan—breast cancer	0.00142	0.00523	CbGbCtD
Dasatinib—ABCB1—Vinblastine—breast cancer	0.00127	0.00465	CbGbCtD
Dasatinib—CYP3A4—Vinorelbine—breast cancer	0.00123	0.00452	CbGbCtD
Dasatinib—CYP3A4—Tamoxifen—breast cancer	0.00111	0.00408	CbGbCtD
Dasatinib—CYP3A4—Mitoxantrone—breast cancer	0.00108	0.00398	CbGbCtD
Dasatinib—ABCB1—Docetaxel—breast cancer	0.00104	0.00383	CbGbCtD
Dasatinib—CYP3A4—Paclitaxel—breast cancer	0.000865	0.00318	CbGbCtD
Dasatinib—CYP3A4—Irinotecan—breast cancer	0.000853	0.00314	CbGbCtD
Dasatinib—ABCB1—Doxorubicin—breast cancer	0.000778	0.00286	CbGbCtD
Dasatinib—CYP3A4—Vinblastine—breast cancer	0.000759	0.00279	CbGbCtD
Dasatinib—ABCB1—Methotrexate—breast cancer	0.000754	0.00277	CbGbCtD
Dasatinib—CYP3A4—Docetaxel—breast cancer	0.000625	0.0023	CbGbCtD
Dasatinib—CYP3A4—Doxorubicin—breast cancer	0.000466	0.00171	CbGbCtD
Dasatinib—TESK1—Estradiol—Fulvestrant—breast cancer	0.000442	0.215	CbGdCrCtD
Dasatinib—ABL1—Topotecan—Irinotecan—breast cancer	0.000175	0.0851	CbGdCrCtD
Dasatinib—SRC—epithelium—breast cancer	0.000136	0.00189	CbGeAlD
Dasatinib—EPHA4—female reproductive system—breast cancer	0.000136	0.00189	CbGeAlD
Dasatinib—KIT—embryo—breast cancer	0.000136	0.00189	CbGeAlD
Dasatinib—FGR—adipose tissue—breast cancer	0.000135	0.00189	CbGeAlD
Dasatinib—LCK—adipose tissue—breast cancer	0.000135	0.00189	CbGeAlD
Dasatinib—ABL2—female gonad—breast cancer	0.000135	0.00188	CbGeAlD
Dasatinib—ERBB3—female reproductive system—breast cancer	0.000134	0.00187	CbGeAlD
Dasatinib—SIK1—adrenal gland—breast cancer	0.000134	0.00186	CbGeAlD
Dasatinib—MAP3K2—female reproductive system—breast cancer	0.000133	0.00185	CbGeAlD
Dasatinib—LIMK2—endocrine gland—breast cancer	0.000133	0.00185	CbGeAlD
Dasatinib—RIPK2—bone marrow—breast cancer	0.000132	0.00185	CbGeAlD
Dasatinib—PDGFRB—embryo—breast cancer	0.000132	0.00185	CbGeAlD
Dasatinib—EPHA4—adrenal gland—breast cancer	0.000132	0.00184	CbGeAlD
Dasatinib—EPHB4—uterus—breast cancer	0.000132	0.00184	CbGeAlD
Dasatinib—FMO3—pituitary gland—breast cancer	0.000131	0.00183	CbGeAlD
Dasatinib—EPHB6—endometrium—breast cancer	0.000131	0.00182	CbGeAlD
Dasatinib—FMO3—adipose tissue—breast cancer	0.000131	0.00182	CbGeAlD
Dasatinib—STAT5B—lymph node—breast cancer	0.000131	0.00182	CbGeAlD
Dasatinib—MAP3K2—adrenal gland—breast cancer	0.00013	0.00181	CbGeAlD
Dasatinib—EPHB4—pituitary gland—breast cancer	0.000129	0.00181	CbGeAlD
Dasatinib—SIK1—bone marrow—breast cancer	0.000129	0.0018	CbGeAlD
Dasatinib—FYN—uterus—breast cancer	0.000129	0.0018	CbGeAlD
Dasatinib—SRC—skin of body—breast cancer	0.000129	0.0018	CbGeAlD
Dasatinib—EPHB4—adipose tissue—breast cancer	0.000129	0.0018	CbGeAlD
Dasatinib—STK35—endocrine gland—breast cancer	0.000129	0.00179	CbGeAlD
Dasatinib—JAK2—pituitary gland—breast cancer	0.000129	0.00179	CbGeAlD
Dasatinib—CSK—Doxorubicin—Idarubicin—breast cancer	0.000128	0.0624	CbGdCrCtD
Dasatinib—CSK—Daunorubicin—Idarubicin—breast cancer	0.000128	0.0624	CbGdCrCtD
Dasatinib—CSK—Epirubicin—Idarubicin—breast cancer	0.000128	0.0624	CbGdCrCtD
Dasatinib—JAK2—adipose tissue—breast cancer	0.000128	0.00179	CbGeAlD
Dasatinib—CSK—endocrine gland—breast cancer	0.000128	0.00178	CbGeAlD
Dasatinib—RIPK2—female gonad—breast cancer	0.000128	0.00178	CbGeAlD
Dasatinib—EPHA2—pituitary gland—breast cancer	0.000127	0.00177	CbGeAlD
Dasatinib—FYN—pituitary gland—breast cancer	0.000127	0.00177	CbGeAlD
Dasatinib—EPHA2—adipose tissue—breast cancer	0.000126	0.00176	CbGeAlD
Dasatinib—YES1—endometrium—breast cancer	0.000126	0.00176	CbGeAlD
Dasatinib—FYN—adipose tissue—breast cancer	0.000126	0.00176	CbGeAlD
Dasatinib—HCK—endocrine gland—breast cancer	0.000126	0.00176	CbGeAlD
Dasatinib—MAP4K5—uterus—breast cancer	0.000126	0.00176	CbGeAlD
Dasatinib—MAP3K2—bone marrow—breast cancer	0.000126	0.00175	CbGeAlD
Dasatinib—MAPK14—female reproductive system—breast cancer	0.000125	0.00174	CbGeAlD
Dasatinib—SIK1—female gonad—breast cancer	0.000125	0.00174	CbGeAlD
Dasatinib—FGR—female reproductive system—breast cancer	0.000125	0.00174	CbGeAlD
Dasatinib—MAP3K3—pituitary gland—breast cancer	0.000124	0.00173	CbGeAlD
Dasatinib—MAP4K5—pituitary gland—breast cancer	0.000124	0.00173	CbGeAlD
Dasatinib—MAP4K5—adipose tissue—breast cancer	0.000123	0.00172	CbGeAlD
Dasatinib—MAP3K3—adipose tissue—breast cancer	0.000123	0.00172	CbGeAlD
Dasatinib—EPHA4—female gonad—breast cancer	0.000123	0.00172	CbGeAlD
Dasatinib—ERBB3—female gonad—breast cancer	0.000122	0.0017	CbGeAlD
Dasatinib—MAPK14—adrenal gland—breast cancer	0.000122	0.0017	CbGeAlD
Dasatinib—FGR—adrenal gland—breast cancer	0.000121	0.00169	CbGeAlD
Dasatinib—LCK—adrenal gland—breast cancer	0.000121	0.00169	CbGeAlD
Dasatinib—MAP3K2—female gonad—breast cancer	0.000121	0.00169	CbGeAlD
Dasatinib—EPHA3—lymph node—breast cancer	0.000121	0.00168	CbGeAlD
Dasatinib—RIPK2—endocrine gland—breast cancer	0.000119	0.00166	CbGeAlD
Dasatinib—EPHB4—female reproductive system—breast cancer	0.000119	0.00165	CbGeAlD
Dasatinib—EPHB6—pituitary gland—breast cancer	0.000118	0.00165	CbGeAlD
Dasatinib—MAPK14—bone marrow—breast cancer	0.000118	0.00165	CbGeAlD
Dasatinib—ABL1—embryo—breast cancer	0.000118	0.00164	CbGeAlD
Dasatinib—EPHB6—adipose tissue—breast cancer	0.000118	0.00164	CbGeAlD
Dasatinib—JAK2—female reproductive system—breast cancer	0.000118	0.00164	CbGeAlD
Dasatinib—FGR—bone marrow—breast cancer	0.000118	0.00164	CbGeAlD
Dasatinib—LCK—bone marrow—breast cancer	0.000118	0.00164	CbGeAlD
Dasatinib—SIK3—lymph node—breast cancer	0.000117	0.00164	CbGeAlD
Dasatinib—FMO3—adrenal gland—breast cancer	0.000117	0.00164	CbGeAlD
Dasatinib—YES1—uterus—breast cancer	0.000117	0.00162	CbGeAlD
Dasatinib—EPHA2—female reproductive system—breast cancer	0.000116	0.00162	CbGeAlD
Dasatinib—FYN—female reproductive system—breast cancer	0.000116	0.00162	CbGeAlD
Dasatinib—SIK1—endocrine gland—breast cancer	0.000116	0.00162	CbGeAlD
Dasatinib—CSF1R—skin of body—breast cancer	0.000116	0.00162	CbGeAlD
Dasatinib—EPHB4—adrenal gland—breast cancer	0.000116	0.00161	CbGeAlD
Dasatinib—JAK2—adrenal gland—breast cancer	0.000115	0.0016	CbGeAlD
Dasatinib—EPHA4—endocrine gland—breast cancer	0.000115	0.0016	CbGeAlD
Dasatinib—YES1—pituitary gland—breast cancer	0.000114	0.0016	CbGeAlD
Dasatinib—PDGFRA—uterus—breast cancer	0.000114	0.00159	CbGeAlD
Dasatinib—YES1—adipose tissue—breast cancer	0.000114	0.00159	CbGeAlD
Dasatinib—MAPK14—female gonad—breast cancer	0.000114	0.00159	CbGeAlD
Dasatinib—ERBB3—endocrine gland—breast cancer	0.000114	0.00158	CbGeAlD
Dasatinib—EPHA2—adrenal gland—breast cancer	0.000113	0.00158	CbGeAlD
Dasatinib—MAP4K5—female reproductive system—breast cancer	0.000113	0.00158	CbGeAlD
Dasatinib—MAP3K3—female reproductive system—breast cancer	0.000113	0.00158	CbGeAlD
Dasatinib—FGR—female gonad—breast cancer	0.000113	0.00158	CbGeAlD
Dasatinib—LCK—female gonad—breast cancer	0.000113	0.00158	CbGeAlD
Dasatinib—FYN—adrenal gland—breast cancer	0.000113	0.00158	CbGeAlD
Dasatinib—MAP3K2—endocrine gland—breast cancer	0.000113	0.00157	CbGeAlD
Dasatinib—MAP2K5—endometrium—breast cancer	0.000112	0.00156	CbGeAlD
Dasatinib—EPHB4—bone marrow—breast cancer	0.000112	0.00156	CbGeAlD
Dasatinib—PDGFRA—adipose tissue—breast cancer	0.000112	0.00156	CbGeAlD
Dasatinib—JAK2—bone marrow—breast cancer	0.000111	0.00155	CbGeAlD
Dasatinib—MAP4K5—adrenal gland—breast cancer	0.000111	0.00154	CbGeAlD
Dasatinib—MAP3K3—adrenal gland—breast cancer	0.000111	0.00154	CbGeAlD
Dasatinib—KIT—epithelium—breast cancer	0.000111	0.00154	CbGeAlD
Dasatinib—SRC—adipose tissue—breast cancer	0.00011	0.00153	CbGeAlD
Dasatinib—FYN—bone marrow—breast cancer	0.00011	0.00153	CbGeAlD
Dasatinib—CSF1R—endometrium—breast cancer	0.000109	0.00152	CbGeAlD
Dasatinib—ZAK—lymph node—breast cancer	0.000109	0.00152	CbGeAlD
Dasatinib—PDGFRB—epithelium—breast cancer	0.000108	0.00151	CbGeAlD
Dasatinib—EPHB4—female gonad—breast cancer	0.000108	0.0015	CbGeAlD
Dasatinib—JAK2—female gonad—breast cancer	0.000107	0.00149	CbGeAlD
Dasatinib—MAP3K3—bone marrow—breast cancer	0.000107	0.00149	CbGeAlD
Dasatinib—MAP4K5—bone marrow—breast cancer	0.000107	0.00149	CbGeAlD
Dasatinib—MAPK14—endocrine gland—breast cancer	0.000106	0.00148	CbGeAlD
Dasatinib—EPHA2—female gonad—breast cancer	0.000106	0.00148	CbGeAlD
Dasatinib—EPHB6—adrenal gland—breast cancer	0.000106	0.00147	CbGeAlD
Dasatinib—FYN—female gonad—breast cancer	0.000106	0.00147	CbGeAlD
Dasatinib—FGR—endocrine gland—breast cancer	0.000105	0.00147	CbGeAlD
Dasatinib—ERBB3—Vinblastine—Vinorelbine—breast cancer	0.000105	0.0513	CbGdCrCtD
Dasatinib—KIT—skin of body—breast cancer	0.000105	0.00147	CbGeAlD
Dasatinib—YES1—female reproductive system—breast cancer	0.000105	0.00146	CbGeAlD
Dasatinib—BMPR1B—lymph node—breast cancer	0.000105	0.00146	CbGeAlD
Dasatinib—BTK—lymph node—breast cancer	0.000104	0.00145	CbGeAlD
Dasatinib—MAP4K5—female gonad—breast cancer	0.000103	0.00144	CbGeAlD
Dasatinib—MAP3K3—female gonad—breast cancer	0.000103	0.00144	CbGeAlD
Dasatinib—PDGFRA—female reproductive system—breast cancer	0.000103	0.00143	CbGeAlD
Dasatinib—PDGFRB—skin of body—breast cancer	0.000103	0.00143	CbGeAlD
Dasatinib—TNK2—lymph node—breast cancer	0.000103	0.00143	CbGeAlD
Dasatinib—YES1—adrenal gland—breast cancer	0.000102	0.00143	CbGeAlD
Dasatinib—FMO3—endocrine gland—breast cancer	0.000102	0.00142	CbGeAlD
Dasatinib—MAP2K5—pituitary gland—breast cancer	0.000101	0.00141	CbGeAlD
Dasatinib—MAP2K5—adipose tissue—breast cancer	0.000101	0.00141	CbGeAlD
Dasatinib—SRC—female reproductive system—breast cancer	0.000101	0.00141	CbGeAlD
Dasatinib—CSF1R—uterus—breast cancer	0.000101	0.0014	CbGeAlD
Dasatinib—EPHB4—endocrine gland—breast cancer	0.0001	0.0014	CbGeAlD
Dasatinib—PDGFRA—adrenal gland—breast cancer	0.0001	0.0014	CbGeAlD
Dasatinib—JAK2—endocrine gland—breast cancer	9.96e-05	0.00139	CbGeAlD
Dasatinib—KIT—endometrium—breast cancer	9.92e-05	0.00138	CbGeAlD
Dasatinib—YES1—bone marrow—breast cancer	9.89e-05	0.00138	CbGeAlD
Dasatinib—CSF1R—pituitary gland—breast cancer	9.88e-05	0.00138	CbGeAlD
Dasatinib—EPHB6—female gonad—breast cancer	9.86e-05	0.00138	CbGeAlD
Dasatinib—CSF1R—adipose tissue—breast cancer	9.84e-05	0.00137	CbGeAlD
Dasatinib—EPHA2—endocrine gland—breast cancer	9.84e-05	0.00137	CbGeAlD
Dasatinib—SRC—adrenal gland—breast cancer	9.83e-05	0.00137	CbGeAlD
Dasatinib—FYN—endocrine gland—breast cancer	9.82e-05	0.00137	CbGeAlD
Dasatinib—PDGFRB—endometrium—breast cancer	9.68e-05	0.00135	CbGeAlD
Dasatinib—TESK1—lymph node—breast cancer	9.65e-05	0.00135	CbGeAlD
Dasatinib—MAP3K3—endocrine gland—breast cancer	9.6e-05	0.00134	CbGeAlD
Dasatinib—MAP4K5—endocrine gland—breast cancer	9.6e-05	0.00134	CbGeAlD
Dasatinib—YES1—female gonad—breast cancer	9.53e-05	0.00133	CbGeAlD
Dasatinib—STK36—lymph node—breast cancer	9.5e-05	0.00132	CbGeAlD
Dasatinib—EPHB3—lymph node—breast cancer	9.5e-05	0.00132	CbGeAlD
Dasatinib—PDGFRA—female gonad—breast cancer	9.35e-05	0.0013	CbGeAlD
Dasatinib—MAP2K5—female reproductive system—breast cancer	9.27e-05	0.00129	CbGeAlD
Dasatinib—LIMK2—lymph node—breast cancer	9.18e-05	0.00128	CbGeAlD
Dasatinib—SRC—female gonad—breast cancer	9.17e-05	0.00128	CbGeAlD
Dasatinib—ABL1—skin of body—breast cancer	9.16e-05	0.00128	CbGeAlD
Dasatinib—KIT—uterus—breast cancer	9.14e-05	0.00127	CbGeAlD
Dasatinib—CSF1R—female reproductive system—breast cancer	9.05e-05	0.00126	CbGeAlD
Dasatinib—MAP2K5—adrenal gland—breast cancer	9.05e-05	0.00126	CbGeAlD
Dasatinib—KIT—pituitary gland—breast cancer	8.97e-05	0.00125	CbGeAlD
Dasatinib—ABL1—Doxorubicin—Idarubicin—breast cancer	8.95e-05	0.0436	CbGdCrCtD
Dasatinib—ABL1—Daunorubicin—Idarubicin—breast cancer	8.95e-05	0.0436	CbGdCrCtD
Dasatinib—ABL1—Epirubicin—Idarubicin—breast cancer	8.95e-05	0.0436	CbGdCrCtD
Dasatinib—KIT—adipose tissue—breast cancer	8.94e-05	0.00125	CbGeAlD
Dasatinib—PDGFRB—uterus—breast cancer	8.92e-05	0.00124	CbGeAlD
Dasatinib—STK35—lymph node—breast cancer	8.9e-05	0.00124	CbGeAlD
Dasatinib—YES1—endocrine gland—breast cancer	8.86e-05	0.00124	CbGeAlD
Dasatinib—CSK—lymph node—breast cancer	8.84e-05	0.00123	CbGeAlD
Dasatinib—CSF1R—adrenal gland—breast cancer	8.83e-05	0.00123	CbGeAlD
Dasatinib—PKMYT1—Danazol—Fluoxymesterone—breast cancer	8.81e-05	0.0429	CbGdCrCtD
Dasatinib—PDGFRB—pituitary gland—breast cancer	8.76e-05	0.00122	CbGeAlD
Dasatinib—PDGFRB—adipose tissue—breast cancer	8.73e-05	0.00122	CbGeAlD
Dasatinib—HCK—lymph node—breast cancer	8.73e-05	0.00122	CbGeAlD
Dasatinib—PDGFRA—endocrine gland—breast cancer	8.7e-05	0.00121	CbGeAlD
Dasatinib—CYP1A2—nipple—breast cancer	8.68e-05	0.00121	CbGeAlD
Dasatinib—ABL2—lymph node—breast cancer	8.67e-05	0.00121	CbGeAlD
Dasatinib—ABL1—endometrium—breast cancer	8.63e-05	0.0012	CbGeAlD
Dasatinib—CYP1A1—nipple—breast cancer	8.56e-05	0.00119	CbGeAlD
Dasatinib—CSF1R—bone marrow—breast cancer	8.54e-05	0.00119	CbGeAlD
Dasatinib—SRC—endocrine gland—breast cancer	8.53e-05	0.00119	CbGeAlD
Dasatinib—MAP2K5—female gonad—breast cancer	8.43e-05	0.00118	CbGeAlD
Dasatinib—CSF1R—female gonad—breast cancer	8.23e-05	0.00115	CbGeAlD
Dasatinib—KIT—female reproductive system—breast cancer	8.21e-05	0.00115	CbGeAlD
Dasatinib—RIPK2—lymph node—breast cancer	8.2e-05	0.00114	CbGeAlD
Dasatinib—PDGFRB—female reproductive system—breast cancer	8.02e-05	0.00112	CbGeAlD
Dasatinib—KIT—adrenal gland—breast cancer	8.02e-05	0.00112	CbGeAlD
Dasatinib—SIK1—lymph node—breast cancer	8.01e-05	0.00112	CbGeAlD
Dasatinib—ABL1—uterus—breast cancer	7.95e-05	0.00111	CbGeAlD
Dasatinib—EPHA4—lymph node—breast cancer	7.93e-05	0.00111	CbGeAlD
Dasatinib—ERBB3—lymph node—breast cancer	7.85e-05	0.0011	CbGeAlD
Dasatinib—MAP2K5—endocrine gland—breast cancer	7.84e-05	0.00109	CbGeAlD
Dasatinib—PDGFRB—adrenal gland—breast cancer	7.83e-05	0.00109	CbGeAlD
Dasatinib—ABL1—pituitary gland—breast cancer	7.81e-05	0.00109	CbGeAlD
Dasatinib—ABL1—adipose tissue—breast cancer	7.78e-05	0.00108	CbGeAlD
Dasatinib—MAP3K2—lymph node—breast cancer	7.78e-05	0.00108	CbGeAlD
Dasatinib—KIT—bone marrow—breast cancer	7.75e-05	0.00108	CbGeAlD
Dasatinib—CYP1B1—skin of body—breast cancer	7.75e-05	0.00108	CbGeAlD
Dasatinib—CSF1R—endocrine gland—breast cancer	7.66e-05	0.00107	CbGeAlD
Dasatinib—PDGFRB—bone marrow—breast cancer	7.57e-05	0.00106	CbGeAlD
Dasatinib—KIT—female gonad—breast cancer	7.47e-05	0.00104	CbGeAlD
Dasatinib—MAPK14—lymph node—breast cancer	7.31e-05	0.00102	CbGeAlD
Dasatinib—PDGFRB—female gonad—breast cancer	7.3e-05	0.00102	CbGeAlD
Dasatinib—FGR—lymph node—breast cancer	7.28e-05	0.00102	CbGeAlD
Dasatinib—LCK—lymph node—breast cancer	7.28e-05	0.00102	CbGeAlD
Dasatinib—ABL1—female reproductive system—breast cancer	7.15e-05	0.000997	CbGeAlD
Dasatinib—FMO3—lymph node—breast cancer	7.03e-05	0.000981	CbGeAlD
Dasatinib—ABL1—adrenal gland—breast cancer	6.98e-05	0.000973	CbGeAlD
Dasatinib—KIT—endocrine gland—breast cancer	6.95e-05	0.000969	CbGeAlD
Dasatinib—EPHB4—lymph node—breast cancer	6.93e-05	0.000967	CbGeAlD
Dasatinib—JAK2—lymph node—breast cancer	6.88e-05	0.00096	CbGeAlD
Dasatinib—EPHA2—lymph node—breast cancer	6.8e-05	0.000948	CbGeAlD
Dasatinib—PDGFRB—endocrine gland—breast cancer	6.79e-05	0.000947	CbGeAlD
Dasatinib—FYN—lymph node—breast cancer	6.79e-05	0.000947	CbGeAlD
Dasatinib—ABL1—bone marrow—breast cancer	6.75e-05	0.000941	CbGeAlD
Dasatinib—CYP1B1—uterus—breast cancer	6.74e-05	0.000939	CbGeAlD
Dasatinib—MAP4K5—lymph node—breast cancer	6.63e-05	0.000925	CbGeAlD
Dasatinib—MAP3K3—lymph node—breast cancer	6.63e-05	0.000925	CbGeAlD
Dasatinib—CYP1B1—pituitary gland—breast cancer	6.62e-05	0.000922	CbGeAlD
Dasatinib—CYP1B1—adipose tissue—breast cancer	6.59e-05	0.000919	CbGeAlD
Dasatinib—ABL1—female gonad—breast cancer	6.51e-05	0.000907	CbGeAlD
Dasatinib—EPHB6—lymph node—breast cancer	6.34e-05	0.000884	CbGeAlD
Dasatinib—TESK1—Dexamethasone—Fluoxymesterone—breast cancer	6.31e-05	0.0307	CbGdCrCtD
Dasatinib—TESK1—Betamethasone—Fluoxymesterone—breast cancer	6.31e-05	0.0307	CbGdCrCtD
Dasatinib—YES1—lymph node—breast cancer	6.13e-05	0.000854	CbGeAlD
Dasatinib—CYP1B1—female reproductive system—breast cancer	6.06e-05	0.000844	CbGeAlD
Dasatinib—ABL1—endocrine gland—breast cancer	6.05e-05	0.000844	CbGeAlD
Dasatinib—PDGFRA—lymph node—breast cancer	6.01e-05	0.000838	CbGeAlD
Dasatinib—CYP1B1—adrenal gland—breast cancer	5.91e-05	0.000824	CbGeAlD
Dasatinib—SRC—lymph node—breast cancer	5.89e-05	0.000822	CbGeAlD
Dasatinib—CSK—Daunorubicin—Epirubicin—breast cancer	5.88e-05	0.0287	CbGdCrCtD
Dasatinib—CSK—Doxorubicin—Epirubicin—breast cancer	5.88e-05	0.0287	CbGdCrCtD
Dasatinib—CYP1A1—epithelium—breast cancer	5.76e-05	0.000804	CbGeAlD
Dasatinib—CYP1B1—female gonad—breast cancer	5.51e-05	0.000768	CbGeAlD
Dasatinib—CYP1A1—skin of body—breast cancer	5.48e-05	0.000764	CbGeAlD
Dasatinib—CSK—Epirubicin—Doxorubicin—breast cancer	5.44e-05	0.0265	CbGdCrCtD
Dasatinib—CSK—Daunorubicin—Doxorubicin—breast cancer	5.44e-05	0.0265	CbGdCrCtD
Dasatinib—ABCG2—endometrium—breast cancer	5.44e-05	0.000759	CbGeAlD
Dasatinib—MAP2K5—lymph node—breast cancer	5.42e-05	0.000756	CbGeAlD
Dasatinib—CSF1R—lymph node—breast cancer	5.29e-05	0.000738	CbGeAlD
Dasatinib—CYP1B1—endocrine gland—breast cancer	5.12e-05	0.000715	CbGeAlD
Dasatinib—ABCG2—uterus—breast cancer	5.02e-05	0.000699	CbGeAlD
Dasatinib—ABCG2—pituitary gland—breast cancer	4.93e-05	0.000687	CbGeAlD
Dasatinib—ABCG2—adipose tissue—breast cancer	4.91e-05	0.000684	CbGeAlD
Dasatinib—KIT—lymph node—breast cancer	4.81e-05	0.00067	CbGeAlD
Dasatinib—CYP1A1—uterus—breast cancer	4.76e-05	0.000664	CbGeAlD
Dasatinib—PDGFRB—lymph node—breast cancer	4.69e-05	0.000654	CbGeAlD
Dasatinib—CYP1A1—adipose tissue—breast cancer	4.66e-05	0.000649	CbGeAlD
Dasatinib—CYP3A5—adipose tissue—breast cancer	4.55e-05	0.000635	CbGeAlD
Dasatinib—ABCG2—adrenal gland—breast cancer	4.4e-05	0.000614	CbGeAlD
Dasatinib—CYP1A1—female reproductive system—breast cancer	4.28e-05	0.000597	CbGeAlD
Dasatinib—ABCG2—bone marrow—breast cancer	4.26e-05	0.000594	CbGeAlD
Dasatinib—ABL1—lymph node—breast cancer	4.18e-05	0.000583	CbGeAlD
Dasatinib—ABL1—Idarubicin—Epirubicin—breast cancer	4.11e-05	0.02	CbGdCrCtD
Dasatinib—ABL1—Doxorubicin—Epirubicin—breast cancer	4.11e-05	0.02	CbGdCrCtD
Dasatinib—ABL1—Daunorubicin—Epirubicin—breast cancer	4.11e-05	0.02	CbGdCrCtD
Dasatinib—ABCG2—female gonad—breast cancer	4.1e-05	0.000572	CbGeAlD
Dasatinib—CYP1A1—female gonad—breast cancer	3.9e-05	0.000543	CbGeAlD
Dasatinib—CYP3A5—female gonad—breast cancer	3.81e-05	0.000531	CbGeAlD
Dasatinib—ABL1—Idarubicin—Doxorubicin—breast cancer	3.8e-05	0.0185	CbGdCrCtD
Dasatinib—ABL1—Daunorubicin—Doxorubicin—breast cancer	3.8e-05	0.0185	CbGdCrCtD
Dasatinib—ABL1—Epirubicin—Doxorubicin—breast cancer	3.8e-05	0.0185	CbGdCrCtD
Dasatinib—CYP1A2—endocrine gland—breast cancer	3.67e-05	0.000512	CbGeAlD
Dasatinib—ABCB1—embryo—breast cancer	3.67e-05	0.000512	CbGeAlD
Dasatinib—CYP1A1—endocrine gland—breast cancer	3.62e-05	0.000505	CbGeAlD
Dasatinib—CYP1B1—lymph node—breast cancer	3.54e-05	0.000494	CbGeAlD
Dasatinib—CYP3A5—endocrine gland—breast cancer	3.54e-05	0.000494	CbGeAlD
Dasatinib—CYP3A4—female reproductive system—breast cancer	3.14e-05	0.000438	CbGeAlD
Dasatinib—ABCB1—epithelium—breast cancer	2.99e-05	0.000417	CbGeAlD
Dasatinib—ABCB1—endometrium—breast cancer	2.68e-05	0.000374	CbGeAlD
Dasatinib—CYP3A4—endocrine gland—breast cancer	2.66e-05	0.000371	CbGeAlD
Dasatinib—ABCG2—lymph node—breast cancer	2.64e-05	0.000368	CbGeAlD
Dasatinib—CYP1A1—lymph node—breast cancer	2.5e-05	0.000349	CbGeAlD
Dasatinib—ABCB1—uterus—breast cancer	2.47e-05	0.000345	CbGeAlD
Dasatinib—ABCB1—pituitary gland—breast cancer	2.43e-05	0.000339	CbGeAlD
Dasatinib—ABCB1—adipose tissue—breast cancer	2.42e-05	0.000337	CbGeAlD
Dasatinib—ABCB1—female reproductive system—breast cancer	2.22e-05	0.00031	CbGeAlD
Dasatinib—ABCB1—adrenal gland—breast cancer	2.17e-05	0.000303	CbGeAlD
Dasatinib—ABCB1—bone marrow—breast cancer	2.1e-05	0.000293	CbGeAlD
Dasatinib—ABCB1—female gonad—breast cancer	2.02e-05	0.000282	CbGeAlD
Dasatinib—ABCB1—endocrine gland—breast cancer	1.88e-05	0.000262	CbGeAlD
Dasatinib—Headache—Gemcitabine—breast cancer	1.32e-05	0.000107	CcSEcCtD
Dasatinib—Musculoskeletal discomfort—Capecitabine—breast cancer	1.32e-05	0.000107	CcSEcCtD
Dasatinib—Cardiac disorder—Epirubicin—breast cancer	1.31e-05	0.000106	CcSEcCtD
Dasatinib—Flushing—Epirubicin—breast cancer	1.31e-05	0.000106	CcSEcCtD
Dasatinib—Vomiting—Fluorouracil—breast cancer	1.31e-05	0.000106	CcSEcCtD
Dasatinib—Dyspepsia—Docetaxel—breast cancer	1.31e-05	0.000106	CcSEcCtD
Dasatinib—Haemorrhage—Doxorubicin—breast cancer	1.31e-05	0.000106	CcSEcCtD
Dasatinib—Hepatitis—Doxorubicin—breast cancer	1.31e-05	0.000106	CcSEcCtD
Dasatinib—Insomnia—Capecitabine—breast cancer	1.31e-05	0.000106	CcSEcCtD
Dasatinib—Rash—Fluorouracil—breast cancer	1.3e-05	0.000106	CcSEcCtD
Dasatinib—Dermatitis—Fluorouracil—breast cancer	1.3e-05	0.000105	CcSEcCtD
Dasatinib—ABCB1—lymph node—breast cancer	1.3e-05	0.000181	CbGeAlD
Dasatinib—Decreased appetite—Docetaxel—breast cancer	1.3e-05	0.000105	CcSEcCtD
Dasatinib—Hypersensitivity—Paclitaxel—breast cancer	1.3e-05	0.000105	CcSEcCtD
Dasatinib—Headache—Fluorouracil—breast cancer	1.3e-05	0.000105	CcSEcCtD
Dasatinib—Urinary tract disorder—Doxorubicin—breast cancer	1.29e-05	0.000105	CcSEcCtD
Dasatinib—Oedema peripheral—Doxorubicin—breast cancer	1.29e-05	0.000105	CcSEcCtD
Dasatinib—Dysgeusia—Methotrexate—breast cancer	1.29e-05	0.000104	CcSEcCtD
Dasatinib—Gastrointestinal disorder—Docetaxel—breast cancer	1.29e-05	0.000104	CcSEcCtD
Dasatinib—Connective tissue disorder—Doxorubicin—breast cancer	1.29e-05	0.000104	CcSEcCtD
Dasatinib—Dyspnoea—Capecitabine—breast cancer	1.29e-05	0.000104	CcSEcCtD
Dasatinib—Fatigue—Docetaxel—breast cancer	1.29e-05	0.000104	CcSEcCtD
Dasatinib—Angiopathy—Epirubicin—breast cancer	1.29e-05	0.000104	CcSEcCtD
Dasatinib—Urethral disorder—Doxorubicin—breast cancer	1.29e-05	0.000104	CcSEcCtD
Dasatinib—Nausea—Mitoxantrone—breast cancer	1.28e-05	0.000104	CcSEcCtD
Dasatinib—Nausea—Irinotecan—breast cancer	1.28e-05	0.000104	CcSEcCtD
Dasatinib—Immune system disorder—Epirubicin—breast cancer	1.28e-05	0.000104	CcSEcCtD
Dasatinib—Mediastinal disorder—Epirubicin—breast cancer	1.28e-05	0.000103	CcSEcCtD
Dasatinib—Constipation—Docetaxel—breast cancer	1.28e-05	0.000103	CcSEcCtD
Dasatinib—Pain—Docetaxel—breast cancer	1.28e-05	0.000103	CcSEcCtD
Dasatinib—Dyspepsia—Capecitabine—breast cancer	1.27e-05	0.000103	CcSEcCtD
Dasatinib—Chills—Epirubicin—breast cancer	1.27e-05	0.000103	CcSEcCtD
Dasatinib—Arrhythmia—Epirubicin—breast cancer	1.27e-05	0.000102	CcSEcCtD
Dasatinib—Visual impairment—Doxorubicin—breast cancer	1.26e-05	0.000102	CcSEcCtD
Dasatinib—Asthenia—Paclitaxel—breast cancer	1.26e-05	0.000102	CcSEcCtD
Dasatinib—Decreased appetite—Capecitabine—breast cancer	1.26e-05	0.000102	CcSEcCtD
Dasatinib—Alopecia—Epirubicin—breast cancer	1.25e-05	0.000101	CcSEcCtD
Dasatinib—Nausea—Gemcitabine—breast cancer	1.25e-05	0.000101	CcSEcCtD
Dasatinib—Gastrointestinal disorder—Capecitabine—breast cancer	1.25e-05	0.000101	CcSEcCtD
Dasatinib—Fatigue—Capecitabine—breast cancer	1.25e-05	0.000101	CcSEcCtD
Dasatinib—Pruritus—Paclitaxel—breast cancer	1.25e-05	0.000101	CcSEcCtD
Dasatinib—Vision blurred—Methotrexate—breast cancer	1.24e-05	0.000101	CcSEcCtD
Dasatinib—Mental disorder—Epirubicin—breast cancer	1.24e-05	0.0001	CcSEcCtD
Dasatinib—Erythema multiforme—Doxorubicin—breast cancer	1.24e-05	0.0001	CcSEcCtD
Dasatinib—Pain—Capecitabine—breast cancer	1.24e-05	0.0001	CcSEcCtD
Dasatinib—Constipation—Capecitabine—breast cancer	1.24e-05	0.0001	CcSEcCtD
Dasatinib—Erythema—Epirubicin—breast cancer	1.23e-05	9.98e-05	CcSEcCtD
Dasatinib—Malnutrition—Epirubicin—breast cancer	1.23e-05	9.98e-05	CcSEcCtD
Dasatinib—Feeling abnormal—Docetaxel—breast cancer	1.23e-05	9.95e-05	CcSEcCtD
Dasatinib—Nausea—Fluorouracil—breast cancer	1.23e-05	9.94e-05	CcSEcCtD
Dasatinib—Eye disorder—Doxorubicin—breast cancer	1.23e-05	9.92e-05	CcSEcCtD
Dasatinib—Ill-defined disorder—Methotrexate—breast cancer	1.22e-05	9.9e-05	CcSEcCtD
Dasatinib—Tinnitus—Doxorubicin—breast cancer	1.22e-05	9.89e-05	CcSEcCtD
Dasatinib—Gastrointestinal pain—Docetaxel—breast cancer	1.22e-05	9.88e-05	CcSEcCtD
Dasatinib—Anaemia—Methotrexate—breast cancer	1.22e-05	9.86e-05	CcSEcCtD
Dasatinib—Flushing—Doxorubicin—breast cancer	1.22e-05	9.85e-05	CcSEcCtD
Dasatinib—Cardiac disorder—Doxorubicin—breast cancer	1.22e-05	9.85e-05	CcSEcCtD
Dasatinib—Dysgeusia—Epirubicin—breast cancer	1.21e-05	9.78e-05	CcSEcCtD
Dasatinib—Diarrhoea—Paclitaxel—breast cancer	1.2e-05	9.75e-05	CcSEcCtD
Dasatinib—Feeling abnormal—Capecitabine—breast cancer	1.19e-05	9.64e-05	CcSEcCtD
Dasatinib—Angiopathy—Doxorubicin—breast cancer	1.19e-05	9.63e-05	CcSEcCtD
Dasatinib—Malaise—Methotrexate—breast cancer	1.19e-05	9.62e-05	CcSEcCtD
Dasatinib—Muscle spasms—Epirubicin—breast cancer	1.19e-05	9.6e-05	CcSEcCtD
Dasatinib—Immune system disorder—Doxorubicin—breast cancer	1.18e-05	9.58e-05	CcSEcCtD
Dasatinib—Vertigo—Methotrexate—breast cancer	1.18e-05	9.58e-05	CcSEcCtD
Dasatinib—Gastrointestinal pain—Capecitabine—breast cancer	1.18e-05	9.56e-05	CcSEcCtD
Dasatinib—Mediastinal disorder—Doxorubicin—breast cancer	1.18e-05	9.56e-05	CcSEcCtD
Dasatinib—Abdominal pain—Docetaxel—breast cancer	1.18e-05	9.55e-05	CcSEcCtD
Dasatinib—Body temperature increased—Docetaxel—breast cancer	1.18e-05	9.55e-05	CcSEcCtD
Dasatinib—Chills—Doxorubicin—breast cancer	1.18e-05	9.52e-05	CcSEcCtD
Dasatinib—Arrhythmia—Doxorubicin—breast cancer	1.17e-05	9.48e-05	CcSEcCtD
Dasatinib—Dizziness—Paclitaxel—breast cancer	1.16e-05	9.42e-05	CcSEcCtD
Dasatinib—Vision blurred—Epirubicin—breast cancer	1.16e-05	9.41e-05	CcSEcCtD
Dasatinib—Alopecia—Doxorubicin—breast cancer	1.16e-05	9.38e-05	CcSEcCtD
Dasatinib—Cough—Methotrexate—breast cancer	1.15e-05	9.31e-05	CcSEcCtD
Dasatinib—Mental disorder—Doxorubicin—breast cancer	1.15e-05	9.3e-05	CcSEcCtD
Dasatinib—Urticaria—Capecitabine—breast cancer	1.15e-05	9.29e-05	CcSEcCtD
Dasatinib—Ill-defined disorder—Epirubicin—breast cancer	1.14e-05	9.26e-05	CcSEcCtD
Dasatinib—Abdominal pain—Capecitabine—breast cancer	1.14e-05	9.24e-05	CcSEcCtD
Dasatinib—Body temperature increased—Capecitabine—breast cancer	1.14e-05	9.24e-05	CcSEcCtD
Dasatinib—Convulsion—Methotrexate—breast cancer	1.14e-05	9.24e-05	CcSEcCtD
Dasatinib—Erythema—Doxorubicin—breast cancer	1.14e-05	9.24e-05	CcSEcCtD
Dasatinib—Malnutrition—Doxorubicin—breast cancer	1.14e-05	9.24e-05	CcSEcCtD
Dasatinib—Anaemia—Epirubicin—breast cancer	1.14e-05	9.23e-05	CcSEcCtD
Dasatinib—Arthralgia—Methotrexate—breast cancer	1.12e-05	9.08e-05	CcSEcCtD
Dasatinib—Myalgia—Methotrexate—breast cancer	1.12e-05	9.08e-05	CcSEcCtD
Dasatinib—Chest pain—Methotrexate—breast cancer	1.12e-05	9.08e-05	CcSEcCtD
Dasatinib—Vomiting—Paclitaxel—breast cancer	1.12e-05	9.06e-05	CcSEcCtD
Dasatinib—Dysgeusia—Doxorubicin—breast cancer	1.12e-05	9.04e-05	CcSEcCtD
Dasatinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—breast cancer	1.11e-05	9.02e-05	CcSEcCtD
Dasatinib—Malaise—Epirubicin—breast cancer	1.11e-05	9e-05	CcSEcCtD
Dasatinib—Rash—Paclitaxel—breast cancer	1.11e-05	8.98e-05	CcSEcCtD
Dasatinib—Dermatitis—Paclitaxel—breast cancer	1.11e-05	8.98e-05	CcSEcCtD
Dasatinib—Discomfort—Methotrexate—breast cancer	1.11e-05	8.97e-05	CcSEcCtD
Dasatinib—Vertigo—Epirubicin—breast cancer	1.11e-05	8.97e-05	CcSEcCtD
Dasatinib—Syncope—Epirubicin—breast cancer	1.11e-05	8.95e-05	CcSEcCtD
Dasatinib—Headache—Paclitaxel—breast cancer	1.1e-05	8.93e-05	CcSEcCtD
Dasatinib—Hypersensitivity—Docetaxel—breast cancer	1.1e-05	8.9e-05	CcSEcCtD
Dasatinib—Muscle spasms—Doxorubicin—breast cancer	1.1e-05	8.88e-05	CcSEcCtD
Dasatinib—Palpitations—Epirubicin—breast cancer	1.09e-05	8.82e-05	CcSEcCtD
Dasatinib—Confusional state—Methotrexate—breast cancer	1.08e-05	8.78e-05	CcSEcCtD
Dasatinib—Loss of consciousness—Epirubicin—breast cancer	1.08e-05	8.77e-05	CcSEcCtD
Dasatinib—Cough—Epirubicin—breast cancer	1.08e-05	8.71e-05	CcSEcCtD
Dasatinib—Vision blurred—Doxorubicin—breast cancer	1.08e-05	8.7e-05	CcSEcCtD
Dasatinib—Asthenia—Docetaxel—breast cancer	1.07e-05	8.67e-05	CcSEcCtD
Dasatinib—Convulsion—Epirubicin—breast cancer	1.07e-05	8.65e-05	CcSEcCtD
Dasatinib—Infection—Methotrexate—breast cancer	1.07e-05	8.65e-05	CcSEcCtD
Dasatinib—Hypertension—Epirubicin—breast cancer	1.06e-05	8.62e-05	CcSEcCtD
Dasatinib—Hypersensitivity—Capecitabine—breast cancer	1.06e-05	8.62e-05	CcSEcCtD
Dasatinib—Ill-defined disorder—Doxorubicin—breast cancer	1.06e-05	8.57e-05	CcSEcCtD
Dasatinib—Pruritus—Docetaxel—breast cancer	1.06e-05	8.55e-05	CcSEcCtD
Dasatinib—Nervous system disorder—Methotrexate—breast cancer	1.05e-05	8.54e-05	CcSEcCtD
Dasatinib—Anaemia—Doxorubicin—breast cancer	1.05e-05	8.54e-05	CcSEcCtD
Dasatinib—Thrombocytopenia—Methotrexate—breast cancer	1.05e-05	8.52e-05	CcSEcCtD
Dasatinib—Arthralgia—Epirubicin—breast cancer	1.05e-05	8.5e-05	CcSEcCtD
Dasatinib—Chest pain—Epirubicin—breast cancer	1.05e-05	8.5e-05	CcSEcCtD
Dasatinib—Myalgia—Epirubicin—breast cancer	1.05e-05	8.5e-05	CcSEcCtD
Dasatinib—Anxiety—Epirubicin—breast cancer	1.05e-05	8.47e-05	CcSEcCtD
Dasatinib—Nausea—Paclitaxel—breast cancer	1.05e-05	8.46e-05	CcSEcCtD
Dasatinib—Skin disorder—Methotrexate—breast cancer	1.04e-05	8.46e-05	CcSEcCtD
Dasatinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—breast cancer	1.04e-05	8.44e-05	CcSEcCtD
Dasatinib—Hyperhidrosis—Methotrexate—breast cancer	1.04e-05	8.42e-05	CcSEcCtD
Dasatinib—Discomfort—Epirubicin—breast cancer	1.04e-05	8.4e-05	CcSEcCtD
Dasatinib—Asthenia—Capecitabine—breast cancer	1.04e-05	8.39e-05	CcSEcCtD
Dasatinib—Malaise—Doxorubicin—breast cancer	1.03e-05	8.33e-05	CcSEcCtD
Dasatinib—Vertigo—Doxorubicin—breast cancer	1.03e-05	8.3e-05	CcSEcCtD
Dasatinib—Anorexia—Methotrexate—breast cancer	1.03e-05	8.3e-05	CcSEcCtD
Dasatinib—Syncope—Doxorubicin—breast cancer	1.02e-05	8.28e-05	CcSEcCtD
Dasatinib—Pruritus—Capecitabine—breast cancer	1.02e-05	8.27e-05	CcSEcCtD
Dasatinib—Diarrhoea—Docetaxel—breast cancer	1.02e-05	8.26e-05	CcSEcCtD
Dasatinib—Confusional state—Epirubicin—breast cancer	1.01e-05	8.21e-05	CcSEcCtD
Dasatinib—Palpitations—Doxorubicin—breast cancer	1.01e-05	8.16e-05	CcSEcCtD
Dasatinib—Oedema—Epirubicin—breast cancer	1.01e-05	8.15e-05	CcSEcCtD
Dasatinib—Hypotension—Methotrexate—breast cancer	1.01e-05	8.13e-05	CcSEcCtD
Dasatinib—Loss of consciousness—Doxorubicin—breast cancer	1e-05	8.12e-05	CcSEcCtD
Dasatinib—Infection—Epirubicin—breast cancer	1e-05	8.09e-05	CcSEcCtD
Dasatinib—Cough—Doxorubicin—breast cancer	9.96e-06	8.06e-05	CcSEcCtD
Dasatinib—Shock—Epirubicin—breast cancer	9.9e-06	8.02e-05	CcSEcCtD
Dasatinib—Convulsion—Doxorubicin—breast cancer	9.89e-06	8e-05	CcSEcCtD
Dasatinib—Diarrhoea—Capecitabine—breast cancer	9.89e-06	8e-05	CcSEcCtD
Dasatinib—Nervous system disorder—Epirubicin—breast cancer	9.87e-06	7.99e-05	CcSEcCtD
Dasatinib—Dizziness—Docetaxel—breast cancer	9.87e-06	7.99e-05	CcSEcCtD
Dasatinib—Thrombocytopenia—Epirubicin—breast cancer	9.86e-06	7.98e-05	CcSEcCtD
Dasatinib—Hypertension—Doxorubicin—breast cancer	9.85e-06	7.97e-05	CcSEcCtD
Dasatinib—Tachycardia—Epirubicin—breast cancer	9.82e-06	7.95e-05	CcSEcCtD
Dasatinib—Musculoskeletal discomfort—Methotrexate—breast cancer	9.8e-06	7.93e-05	CcSEcCtD
Dasatinib—Skin disorder—Epirubicin—breast cancer	9.78e-06	7.91e-05	CcSEcCtD
Dasatinib—Hyperhidrosis—Epirubicin—breast cancer	9.73e-06	7.88e-05	CcSEcCtD
Dasatinib—Insomnia—Methotrexate—breast cancer	9.73e-06	7.87e-05	CcSEcCtD
Dasatinib—Chest pain—Doxorubicin—breast cancer	9.72e-06	7.86e-05	CcSEcCtD
Dasatinib—Myalgia—Doxorubicin—breast cancer	9.72e-06	7.86e-05	CcSEcCtD
Dasatinib—Arthralgia—Doxorubicin—breast cancer	9.72e-06	7.86e-05	CcSEcCtD
Dasatinib—Anxiety—Doxorubicin—breast cancer	9.68e-06	7.84e-05	CcSEcCtD
Dasatinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—breast cancer	9.65e-06	7.81e-05	CcSEcCtD
Dasatinib—Discomfort—Doxorubicin—breast cancer	9.6e-06	7.77e-05	CcSEcCtD
Dasatinib—Anorexia—Epirubicin—breast cancer	9.59e-06	7.77e-05	CcSEcCtD
Dasatinib—Dyspnoea—Methotrexate—breast cancer	9.59e-06	7.76e-05	CcSEcCtD
Dasatinib—Somnolence—Methotrexate—breast cancer	9.56e-06	7.74e-05	CcSEcCtD
Dasatinib—Dizziness—Capecitabine—breast cancer	9.55e-06	7.73e-05	CcSEcCtD
Dasatinib—Vomiting—Docetaxel—breast cancer	9.49e-06	7.68e-05	CcSEcCtD
Dasatinib—Dyspepsia—Methotrexate—breast cancer	9.47e-06	7.66e-05	CcSEcCtD
Dasatinib—Rash—Docetaxel—breast cancer	9.41e-06	7.62e-05	CcSEcCtD
Dasatinib—Hypotension—Epirubicin—breast cancer	9.41e-06	7.61e-05	CcSEcCtD
Dasatinib—Dermatitis—Docetaxel—breast cancer	9.4e-06	7.61e-05	CcSEcCtD
Dasatinib—Confusional state—Doxorubicin—breast cancer	9.39e-06	7.6e-05	CcSEcCtD
Dasatinib—Decreased appetite—Methotrexate—breast cancer	9.35e-06	7.57e-05	CcSEcCtD
Dasatinib—Headache—Docetaxel—breast cancer	9.35e-06	7.57e-05	CcSEcCtD
Dasatinib—Oedema—Doxorubicin—breast cancer	9.31e-06	7.54e-05	CcSEcCtD
Dasatinib—Gastrointestinal disorder—Methotrexate—breast cancer	9.29e-06	7.52e-05	CcSEcCtD
Dasatinib—Fatigue—Methotrexate—breast cancer	9.27e-06	7.51e-05	CcSEcCtD
Dasatinib—Infection—Doxorubicin—breast cancer	9.25e-06	7.49e-05	CcSEcCtD
Dasatinib—Pain—Methotrexate—breast cancer	9.2e-06	7.44e-05	CcSEcCtD
Dasatinib—Vomiting—Capecitabine—breast cancer	9.19e-06	7.44e-05	CcSEcCtD
Dasatinib—Musculoskeletal discomfort—Epirubicin—breast cancer	9.17e-06	7.42e-05	CcSEcCtD
Dasatinib—Shock—Doxorubicin—breast cancer	9.16e-06	7.42e-05	CcSEcCtD
Dasatinib—Nervous system disorder—Doxorubicin—breast cancer	9.13e-06	7.39e-05	CcSEcCtD
Dasatinib—Thrombocytopenia—Doxorubicin—breast cancer	9.12e-06	7.38e-05	CcSEcCtD
Dasatinib—Rash—Capecitabine—breast cancer	9.11e-06	7.37e-05	CcSEcCtD
Dasatinib—Insomnia—Epirubicin—breast cancer	9.1e-06	7.37e-05	CcSEcCtD
Dasatinib—Dermatitis—Capecitabine—breast cancer	9.1e-06	7.37e-05	CcSEcCtD
Dasatinib—Tachycardia—Doxorubicin—breast cancer	9.09e-06	7.36e-05	CcSEcCtD
Dasatinib—Headache—Capecitabine—breast cancer	9.05e-06	7.33e-05	CcSEcCtD
Dasatinib—Skin disorder—Doxorubicin—breast cancer	9.05e-06	7.32e-05	CcSEcCtD
Dasatinib—Hyperhidrosis—Doxorubicin—breast cancer	9e-06	7.29e-05	CcSEcCtD
Dasatinib—Dyspnoea—Epirubicin—breast cancer	8.97e-06	7.26e-05	CcSEcCtD
Dasatinib—Somnolence—Epirubicin—breast cancer	8.95e-06	7.24e-05	CcSEcCtD
Dasatinib—Anorexia—Doxorubicin—breast cancer	8.88e-06	7.19e-05	CcSEcCtD
Dasatinib—Nausea—Docetaxel—breast cancer	8.86e-06	7.17e-05	CcSEcCtD
Dasatinib—Feeling abnormal—Methotrexate—breast cancer	8.86e-06	7.17e-05	CcSEcCtD
Dasatinib—Dyspepsia—Epirubicin—breast cancer	8.86e-06	7.17e-05	CcSEcCtD
Dasatinib—Gastrointestinal pain—Methotrexate—breast cancer	8.8e-06	7.12e-05	CcSEcCtD
Dasatinib—Decreased appetite—Epirubicin—breast cancer	8.75e-06	7.08e-05	CcSEcCtD
Dasatinib—Hypotension—Doxorubicin—breast cancer	8.7e-06	7.04e-05	CcSEcCtD
Dasatinib—Gastrointestinal disorder—Epirubicin—breast cancer	8.69e-06	7.03e-05	CcSEcCtD
Dasatinib—Fatigue—Epirubicin—breast cancer	8.68e-06	7.02e-05	CcSEcCtD
Dasatinib—Constipation—Epirubicin—breast cancer	8.61e-06	6.97e-05	CcSEcCtD
Dasatinib—Pain—Epirubicin—breast cancer	8.61e-06	6.97e-05	CcSEcCtD
Dasatinib—Nausea—Capecitabine—breast cancer	8.58e-06	6.95e-05	CcSEcCtD
Dasatinib—Urticaria—Methotrexate—breast cancer	8.54e-06	6.92e-05	CcSEcCtD
Dasatinib—Abdominal pain—Methotrexate—breast cancer	8.5e-06	6.88e-05	CcSEcCtD
Dasatinib—Body temperature increased—Methotrexate—breast cancer	8.5e-06	6.88e-05	CcSEcCtD
Dasatinib—Musculoskeletal discomfort—Doxorubicin—breast cancer	8.49e-06	6.87e-05	CcSEcCtD
Dasatinib—Insomnia—Doxorubicin—breast cancer	8.42e-06	6.82e-05	CcSEcCtD
Dasatinib—Dyspnoea—Doxorubicin—breast cancer	8.3e-06	6.72e-05	CcSEcCtD
Dasatinib—Feeling abnormal—Epirubicin—breast cancer	8.29e-06	6.71e-05	CcSEcCtD
Dasatinib—Somnolence—Doxorubicin—breast cancer	8.28e-06	6.7e-05	CcSEcCtD
Dasatinib—Gastrointestinal pain—Epirubicin—breast cancer	8.23e-06	6.66e-05	CcSEcCtD
Dasatinib—Dyspepsia—Doxorubicin—breast cancer	8.2e-06	6.64e-05	CcSEcCtD
Dasatinib—Decreased appetite—Doxorubicin—breast cancer	8.1e-06	6.55e-05	CcSEcCtD
Dasatinib—Gastrointestinal disorder—Doxorubicin—breast cancer	8.04e-06	6.51e-05	CcSEcCtD
Dasatinib—Fatigue—Doxorubicin—breast cancer	8.03e-06	6.5e-05	CcSEcCtD
Dasatinib—Urticaria—Epirubicin—breast cancer	8e-06	6.47e-05	CcSEcCtD
Dasatinib—Constipation—Doxorubicin—breast cancer	7.96e-06	6.45e-05	CcSEcCtD
Dasatinib—Pain—Doxorubicin—breast cancer	7.96e-06	6.45e-05	CcSEcCtD
Dasatinib—Abdominal pain—Epirubicin—breast cancer	7.96e-06	6.44e-05	CcSEcCtD
Dasatinib—Body temperature increased—Epirubicin—breast cancer	7.96e-06	6.44e-05	CcSEcCtD
Dasatinib—Hypersensitivity—Methotrexate—breast cancer	7.92e-06	6.41e-05	CcSEcCtD
Dasatinib—Asthenia—Methotrexate—breast cancer	7.72e-06	6.25e-05	CcSEcCtD
Dasatinib—Feeling abnormal—Doxorubicin—breast cancer	7.67e-06	6.21e-05	CcSEcCtD
Dasatinib—Gastrointestinal pain—Doxorubicin—breast cancer	7.62e-06	6.16e-05	CcSEcCtD
Dasatinib—Pruritus—Methotrexate—breast cancer	7.61e-06	6.16e-05	CcSEcCtD
Dasatinib—Hypersensitivity—Epirubicin—breast cancer	7.42e-06	6e-05	CcSEcCtD
Dasatinib—Urticaria—Doxorubicin—breast cancer	7.4e-06	5.99e-05	CcSEcCtD
Dasatinib—Abdominal pain—Doxorubicin—breast cancer	7.36e-06	5.96e-05	CcSEcCtD
Dasatinib—Body temperature increased—Doxorubicin—breast cancer	7.36e-06	5.96e-05	CcSEcCtD
Dasatinib—Diarrhoea—Methotrexate—breast cancer	7.36e-06	5.96e-05	CcSEcCtD
Dasatinib—Asthenia—Epirubicin—breast cancer	7.22e-06	5.85e-05	CcSEcCtD
Dasatinib—Pruritus—Epirubicin—breast cancer	7.12e-06	5.76e-05	CcSEcCtD
Dasatinib—Dizziness—Methotrexate—breast cancer	7.11e-06	5.76e-05	CcSEcCtD
Dasatinib—Diarrhoea—Epirubicin—breast cancer	6.89e-06	5.57e-05	CcSEcCtD
Dasatinib—Hypersensitivity—Doxorubicin—breast cancer	6.86e-06	5.55e-05	CcSEcCtD
Dasatinib—Vomiting—Methotrexate—breast cancer	6.84e-06	5.53e-05	CcSEcCtD
Dasatinib—Rash—Methotrexate—breast cancer	6.78e-06	5.49e-05	CcSEcCtD
Dasatinib—Dermatitis—Methotrexate—breast cancer	6.78e-06	5.48e-05	CcSEcCtD
Dasatinib—Headache—Methotrexate—breast cancer	6.74e-06	5.45e-05	CcSEcCtD
Dasatinib—Asthenia—Doxorubicin—breast cancer	6.68e-06	5.41e-05	CcSEcCtD
Dasatinib—Dizziness—Epirubicin—breast cancer	6.66e-06	5.39e-05	CcSEcCtD
Dasatinib—Pruritus—Doxorubicin—breast cancer	6.59e-06	5.33e-05	CcSEcCtD
Dasatinib—Vomiting—Epirubicin—breast cancer	6.4e-06	5.18e-05	CcSEcCtD
Dasatinib—Nausea—Methotrexate—breast cancer	6.39e-06	5.17e-05	CcSEcCtD
Dasatinib—Diarrhoea—Doxorubicin—breast cancer	6.37e-06	5.16e-05	CcSEcCtD
Dasatinib—Rash—Epirubicin—breast cancer	6.35e-06	5.14e-05	CcSEcCtD
Dasatinib—Dermatitis—Epirubicin—breast cancer	6.34e-06	5.13e-05	CcSEcCtD
Dasatinib—Headache—Epirubicin—breast cancer	6.31e-06	5.1e-05	CcSEcCtD
Dasatinib—Dizziness—Doxorubicin—breast cancer	6.16e-06	4.98e-05	CcSEcCtD
Dasatinib—Nausea—Epirubicin—breast cancer	5.98e-06	4.84e-05	CcSEcCtD
Dasatinib—Vomiting—Doxorubicin—breast cancer	5.92e-06	4.79e-05	CcSEcCtD
Dasatinib—Rash—Doxorubicin—breast cancer	5.87e-06	4.75e-05	CcSEcCtD
Dasatinib—Dermatitis—Doxorubicin—breast cancer	5.87e-06	4.75e-05	CcSEcCtD
Dasatinib—Headache—Doxorubicin—breast cancer	5.83e-06	4.72e-05	CcSEcCtD
Dasatinib—Nausea—Doxorubicin—breast cancer	5.53e-06	4.48e-05	CcSEcCtD
Dasatinib—SRC—Signaling Pathways—NOS3—breast cancer	1.79e-07	1.31e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—GSTP1—breast cancer	1.78e-07	1.3e-06	CbGpPWpGaD
Dasatinib—JAK2—Immune System—IL6—breast cancer	1.78e-07	1.3e-06	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—PIK3CD—breast cancer	1.78e-07	1.3e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—VEGFA—breast cancer	1.78e-07	1.3e-06	CbGpPWpGaD
Dasatinib—LCK—Disease—KRAS—breast cancer	1.77e-07	1.29e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—HMOX1—breast cancer	1.76e-07	1.29e-06	CbGpPWpGaD
Dasatinib—LCK—Immune System—PIK3CA—breast cancer	1.76e-07	1.29e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—STAT3—breast cancer	1.76e-07	1.29e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—ITPR1—breast cancer	1.76e-07	1.28e-06	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—ALB—breast cancer	1.75e-07	1.28e-06	CbGpPWpGaD
Dasatinib—LYN—Immune System—AKT1—breast cancer	1.75e-07	1.28e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—CDKN1B—breast cancer	1.75e-07	1.28e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—VEGFA—breast cancer	1.75e-07	1.28e-06	CbGpPWpGaD
Dasatinib—ABL1—Immune System—AKT1—breast cancer	1.75e-07	1.28e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—MAPK3—breast cancer	1.74e-07	1.27e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—FASN—breast cancer	1.74e-07	1.27e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—STAT3—breast cancer	1.73e-07	1.27e-06	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—AKT1—breast cancer	1.73e-07	1.27e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—BCHE—breast cancer	1.73e-07	1.26e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—SRC—breast cancer	1.73e-07	1.26e-06	CbGpPWpGaD
Dasatinib—FYN—Disease—IL6—breast cancer	1.73e-07	1.26e-06	CbGpPWpGaD
Dasatinib—FYN—Immune System—AKT1—breast cancer	1.73e-07	1.26e-06	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—HRAS—breast cancer	1.72e-07	1.26e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—MAPK3—breast cancer	1.72e-07	1.25e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—CASP3—breast cancer	1.72e-07	1.25e-06	CbGpPWpGaD
Dasatinib—JAK2—Disease—HRAS—breast cancer	1.72e-07	1.25e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—IL2—breast cancer	1.71e-07	1.25e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—KRAS—breast cancer	1.71e-07	1.25e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—SLC5A5—breast cancer	1.71e-07	1.25e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—SRC—breast cancer	1.71e-07	1.25e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—MDM2—breast cancer	1.7e-07	1.24e-06	CbGpPWpGaD
Dasatinib—SRC—Immune System—KRAS—breast cancer	1.7e-07	1.24e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—MYC—breast cancer	1.69e-07	1.24e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—RAF1—breast cancer	1.69e-07	1.24e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—TGFB1—breast cancer	1.69e-07	1.23e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—ABCB1—breast cancer	1.69e-07	1.23e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—RELA—breast cancer	1.68e-07	1.23e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—VEGFA—breast cancer	1.68e-07	1.23e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—MAPK3—breast cancer	1.68e-07	1.23e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—PIK3CD—breast cancer	1.68e-07	1.23e-06	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—NOS3—breast cancer	1.68e-07	1.23e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—CAV1—breast cancer	1.67e-07	1.22e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—ERBB2—breast cancer	1.67e-07	1.22e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—CCND1—breast cancer	1.67e-07	1.22e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—MYC—breast cancer	1.67e-07	1.22e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—STAT3—breast cancer	1.67e-07	1.22e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—JUN—breast cancer	1.67e-07	1.22e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—TGFB1—breast cancer	1.67e-07	1.22e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—VEGFA—breast cancer	1.66e-07	1.22e-06	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—AKT1—breast cancer	1.66e-07	1.21e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—PIK3CA—breast cancer	1.66e-07	1.21e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—TYMS—breast cancer	1.66e-07	1.21e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—ALB—breast cancer	1.66e-07	1.21e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—EGFR—breast cancer	1.66e-07	1.21e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—MAPK3—breast cancer	1.66e-07	1.21e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—CTNNB1—breast cancer	1.65e-07	1.21e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—AKT1—breast cancer	1.65e-07	1.21e-06	CbGpPWpGaD
Dasatinib—MAPK14—Gene Expression—AKT1—breast cancer	1.65e-07	1.21e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—MTOR—breast cancer	1.65e-07	1.21e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—PIK3CB—breast cancer	1.65e-07	1.21e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—NQO1—breast cancer	1.65e-07	1.21e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—SLC2A1—breast cancer	1.65e-07	1.21e-06	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—IL6—breast cancer	1.65e-07	1.2e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—STAT3—breast cancer	1.65e-07	1.2e-06	CbGpPWpGaD
Dasatinib—JAK2—Disease—IL6—breast cancer	1.64e-07	1.2e-06	CbGpPWpGaD
Dasatinib—JAK2—Immune System—AKT1—breast cancer	1.64e-07	1.2e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—PLA2G4A—breast cancer	1.64e-07	1.2e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—GSTM1—breast cancer	1.64e-07	1.2e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—NCOR1—breast cancer	1.64e-07	1.2e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—MYC—breast cancer	1.64e-07	1.19e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—EGFR—breast cancer	1.63e-07	1.19e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—TGFB1—breast cancer	1.63e-07	1.19e-06	CbGpPWpGaD
Dasatinib—LCK—Immune System—HRAS—breast cancer	1.63e-07	1.19e-06	CbGpPWpGaD
Dasatinib—LCK—Disease—PIK3CA—breast cancer	1.62e-07	1.19e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—MMP9—breast cancer	1.62e-07	1.19e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—CDKN1A—breast cancer	1.62e-07	1.18e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—PTEN—breast cancer	1.61e-07	1.18e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—MYC—breast cancer	1.61e-07	1.18e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—TP53—breast cancer	1.61e-07	1.17e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—TGFB1—breast cancer	1.61e-07	1.17e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—EGFR—breast cancer	1.6e-07	1.17e-06	CbGpPWpGaD
Dasatinib—FYN—Disease—AKT1—breast cancer	1.59e-07	1.16e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—MAPK3—breast cancer	1.59e-07	1.16e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—CXCL8—breast cancer	1.59e-07	1.16e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—NOS3—breast cancer	1.59e-07	1.16e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—CYP1B1—breast cancer	1.58e-07	1.16e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—MAPK8—breast cancer	1.58e-07	1.15e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—EGFR—breast cancer	1.57e-07	1.15e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—PIK3CA—breast cancer	1.57e-07	1.15e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—MAPK3—breast cancer	1.57e-07	1.15e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—GPX1—breast cancer	1.57e-07	1.15e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—KRAS—breast cancer	1.57e-07	1.14e-06	CbGpPWpGaD
Dasatinib—LCK—Immune System—IL6—breast cancer	1.56e-07	1.14e-06	CbGpPWpGaD
Dasatinib—SRC—Immune System—PIK3CA—breast cancer	1.56e-07	1.14e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—CYP1A1—breast cancer	1.55e-07	1.14e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—HSP90AA1—breast cancer	1.55e-07	1.13e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—CDKN1B—breast cancer	1.55e-07	1.13e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—MYC—breast cancer	1.55e-07	1.13e-06	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—PIK3CB—breast cancer	1.55e-07	1.13e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—TGFB1—breast cancer	1.55e-07	1.13e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—KRAS—breast cancer	1.54e-07	1.13e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—ERCC2—breast cancer	1.54e-07	1.13e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—HRAS—breast cancer	1.54e-07	1.12e-06	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—PTGS2—breast cancer	1.54e-07	1.12e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—MYC—breast cancer	1.53e-07	1.12e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—TGFB1—breast cancer	1.53e-07	1.12e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—PIK3CG—breast cancer	1.53e-07	1.11e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—TP53—breast cancer	1.52e-07	1.11e-06	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—AKT1—breast cancer	1.52e-07	1.11e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—CASP3—breast cancer	1.52e-07	1.11e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—IL2—breast cancer	1.52e-07	1.11e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—EGFR—breast cancer	1.52e-07	1.11e-06	CbGpPWpGaD
Dasatinib—JAK2—Disease—AKT1—breast cancer	1.52e-07	1.11e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—KRAS—breast cancer	1.51e-07	1.1e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—NCOA1—breast cancer	1.51e-07	1.1e-06	CbGpPWpGaD
Dasatinib—LCK—Disease—HRAS—breast cancer	1.5e-07	1.1e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—EGFR—breast cancer	1.5e-07	1.09e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—SRC—breast cancer	1.5e-07	1.09e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—STK11—breast cancer	1.49e-07	1.09e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—CYP19A1—breast cancer	1.49e-07	1.09e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—KRAS—breast cancer	1.49e-07	1.09e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—CCND1—breast cancer	1.48e-07	1.08e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—JUN—breast cancer	1.48e-07	1.08e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—IL6—breast cancer	1.47e-07	1.08e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—CTNNB1—breast cancer	1.46e-07	1.07e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—PIK3CB—breast cancer	1.46e-07	1.07e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—VEGFA—breast cancer	1.46e-07	1.06e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—HRAS—breast cancer	1.46e-07	1.06e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—PTGS2—breast cancer	1.45e-07	1.06e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—MTHFR—breast cancer	1.45e-07	1.06e-06	CbGpPWpGaD
Dasatinib—CYP1B1—Metabolism—PIK3CA—breast cancer	1.45e-07	1.06e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—STAT3—breast cancer	1.44e-07	1.05e-06	CbGpPWpGaD
Dasatinib—SRC—Immune System—HRAS—breast cancer	1.44e-07	1.05e-06	CbGpPWpGaD
Dasatinib—LCK—Disease—IL6—breast cancer	1.44e-07	1.05e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—PIK3CA—breast cancer	1.44e-07	1.05e-06	CbGpPWpGaD
Dasatinib—LCK—Immune System—AKT1—breast cancer	1.44e-07	1.05e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—MMP9—breast cancer	1.44e-07	1.05e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—KRAS—breast cancer	1.43e-07	1.05e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—CDKN1A—breast cancer	1.43e-07	1.05e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—PTEN—breast cancer	1.43e-07	1.04e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—PIK3CA—breast cancer	1.42e-07	1.04e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—KRAS—breast cancer	1.41e-07	1.03e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—MAPK8—breast cancer	1.4e-07	1.02e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—IL6—breast cancer	1.39e-07	1.02e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—PIK3CA—breast cancer	1.39e-07	1.01e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—COMT—breast cancer	1.38e-07	1.01e-06	CbGpPWpGaD
Dasatinib—SRC—Immune System—IL6—breast cancer	1.38e-07	1.01e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—MAPK3—breast cancer	1.38e-07	1.01e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—GSTP1—breast cancer	1.38e-07	1.01e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—TP53—breast cancer	1.37e-07	1e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—PIK3CA—breast cancer	1.37e-07	9.98e-07	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—HMOX1—breast cancer	1.36e-07	9.93e-07	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—AKT1—breast cancer	1.36e-07	9.92e-07	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—ITPR1—breast cancer	1.36e-07	9.9e-07	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—TP53—breast cancer	1.34e-07	9.81e-07	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—PIK3CD—breast cancer	1.34e-07	9.8e-07	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—MYC—breast cancer	1.34e-07	9.79e-07	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—PTEN—breast cancer	1.34e-07	9.78e-07	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—CAV1—breast cancer	1.34e-07	9.77e-07	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—TGFB1—breast cancer	1.34e-07	9.77e-07	CbGpPWpGaD
Dasatinib—SRC—Disease—HRAS—breast cancer	1.33e-07	9.72e-07	CbGpPWpGaD
Dasatinib—LCK—Disease—AKT1—breast cancer	1.33e-07	9.7e-07	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—ALB—breast cancer	1.32e-07	9.67e-07	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—TP53—breast cancer	1.32e-07	9.66e-07	CbGpPWpGaD
Dasatinib—ABCG2—Metabolism—PIK3CA—breast cancer	1.32e-07	9.63e-07	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—PIK3CA—breast cancer	1.32e-07	9.61e-07	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—HRAS—breast cancer	1.31e-07	9.58e-07	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—EGFR—breast cancer	1.31e-07	9.58e-07	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—ABCB1—breast cancer	1.3e-07	9.53e-07	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—PIK3CA—breast cancer	1.3e-07	9.49e-07	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—VEGFA—breast cancer	1.29e-07	9.42e-07	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—AKT1—breast cancer	1.29e-07	9.39e-07	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—HRAS—breast cancer	1.28e-07	9.38e-07	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—TYMS—breast cancer	1.28e-07	9.36e-07	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	1.28e-07	9.33e-07	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—STAT3—breast cancer	1.28e-07	9.33e-07	CbGpPWpGaD
Dasatinib—SRC—Disease—IL6—breast cancer	1.27e-07	9.3e-07	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—TP53—breast cancer	1.27e-07	9.3e-07	CbGpPWpGaD
Dasatinib—SRC—Immune System—AKT1—breast cancer	1.27e-07	9.3e-07	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—NOS3—breast cancer	1.27e-07	9.25e-07	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—PLA2G4A—breast cancer	1.27e-07	9.25e-07	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—GSTM1—breast cancer	1.27e-07	9.25e-07	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—NCOR1—breast cancer	1.27e-07	9.25e-07	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—PTEN—breast cancer	1.26e-07	9.24e-07	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—HRAS—breast cancer	1.26e-07	9.24e-07	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—TP53—breast cancer	1.26e-07	9.18e-07	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—IL6—breast cancer	1.26e-07	9.17e-07	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—KRAS—breast cancer	1.24e-07	9.05e-07	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—IL6—breast cancer	1.23e-07	8.98e-07	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—MAPK3—breast cancer	1.22e-07	8.91e-07	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—PIK3CG—breast cancer	1.22e-07	8.9e-07	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—HRAS—breast cancer	1.22e-07	8.89e-07	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—GPX1—breast cancer	1.21e-07	8.86e-07	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—IL6—breast cancer	1.21e-07	8.84e-07	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—HRAS—breast cancer	1.2e-07	8.78e-07	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—CYP1A1—breast cancer	1.2e-07	8.77e-07	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—ERCC2—breast cancer	1.19e-07	8.7e-07	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—MYC—breast cancer	1.19e-07	8.67e-07	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—TGFB1—breast cancer	1.18e-07	8.65e-07	CbGpPWpGaD
Dasatinib—CYP1B1—Metabolism—AKT1—breast cancer	1.18e-07	8.65e-07	CbGpPWpGaD
Dasatinib—SRC—Disease—AKT1—breast cancer	1.18e-07	8.58e-07	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—PIK3CB—breast cancer	1.17e-07	8.54e-07	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—IL6—breast cancer	1.17e-07	8.51e-07	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—EGFR—breast cancer	1.16e-07	8.48e-07	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—PTGS2—breast cancer	1.16e-07	8.46e-07	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—AKT1—breast cancer	1.16e-07	8.46e-07	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—IL6—breast cancer	1.15e-07	8.4e-07	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—PIK3CA—breast cancer	1.14e-07	8.31e-07	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—AKT1—breast cancer	1.13e-07	8.28e-07	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—MTHFR—breast cancer	1.12e-07	8.17e-07	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—AKT1—breast cancer	1.12e-07	8.16e-07	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—TP53—breast cancer	1.1e-07	8.04e-07	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—KRAS—breast cancer	1.1e-07	8.01e-07	CbGpPWpGaD
Dasatinib—ABCG2—Metabolism—AKT1—breast cancer	1.08e-07	7.87e-07	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—AKT1—breast cancer	1.07e-07	7.85e-07	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—PIK3CD—breast cancer	1.07e-07	7.82e-07	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—AKT1—breast cancer	1.06e-07	7.75e-07	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—ALB—breast cancer	1.06e-07	7.72e-07	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—HRAS—breast cancer	1.05e-07	7.69e-07	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—CAV1—breast cancer	1.03e-07	7.54e-07	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—NOS3—breast cancer	1.01e-07	7.39e-07	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—PTEN—breast cancer	1.01e-07	7.38e-07	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—IL6—breast cancer	1.01e-07	7.36e-07	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—PIK3CA—breast cancer	1.01e-07	7.36e-07	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—TP53—breast cancer	9.74e-08	7.12e-07	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—PIK3CA—breast cancer	9.44e-08	6.9e-07	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—PIK3CG—breast cancer	9.4e-08	6.87e-07	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—PIK3CB—breast cancer	9.33e-08	6.82e-07	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—HRAS—breast cancer	9.32e-08	6.81e-07	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—AKT1—breast cancer	9.29e-08	6.79e-07	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—PTGS2—breast cancer	9.25e-08	6.76e-07	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—PIK3CA—breast cancer	8.92e-08	6.52e-07	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—IL6—breast cancer	8.92e-08	6.52e-07	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—PIK3CD—breast cancer	8.26e-08	6.04e-07	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—AKT1—breast cancer	8.23e-08	6.01e-07	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—ALB—breast cancer	8.16e-08	5.96e-07	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—PTEN—breast cancer	8.06e-08	5.89e-07	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—NOS3—breast cancer	7.8e-08	5.7e-07	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—AKT1—breast cancer	7.72e-08	5.64e-07	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—AKT1—breast cancer	7.29e-08	5.33e-07	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—PIK3CB—breast cancer	7.2e-08	5.26e-07	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—PTGS2—breast cancer	7.14e-08	5.21e-07	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—PIK3CA—breast cancer	7.13e-08	5.21e-07	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—PTEN—breast cancer	6.22e-08	4.55e-07	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—AKT1—breast cancer	5.82e-08	4.25e-07	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—PIK3CA—breast cancer	5.69e-08	4.16e-07	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—AKT1—breast cancer	4.65e-08	3.4e-07	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—PIK3CA—breast cancer	4.39e-08	3.21e-07	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—AKT1—breast cancer	3.59e-08	2.62e-07	CbGpPWpGaD
